Marinus Pharmaceuticals (NASDAQ:MRNS) Lowered to “Sell” at StockNews.com

Marinus Pharmaceuticals (NASDAQ:MRNS) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a report issued on Thursday.

MRNS has been the topic of a number of other research reports. LADENBURG THALM/SH SH downgraded shares of Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, August 14th. Oppenheimer upgraded Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price target on the stock in a report on Monday, September 23rd. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of Marinus Pharmaceuticals in a report on Wednesday, August 14th. Cantor Fitzgerald reissued an “overweight” rating and issued a $13.00 target price on shares of Marinus Pharmaceuticals in a report on Tuesday. Finally, Truist Financial reaffirmed a “buy” rating and set a $10.00 price target on shares of Marinus Pharmaceuticals in a research note on Tuesday, June 18th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $8.83.

Marinus Pharmaceuticals Stock Performance

NASDAQ MRNS opened at $1.84 on Thursday. The stock has a market capitalization of $101.08 million, a price-to-earnings ratio of -0.70 and a beta of 1.13. The business’s 50 day moving average is $1.40 and its two-hundred day moving average is $2.67. Marinus Pharmaceuticals has a 12-month low of $1.05 and a 12-month high of $11.26. The company has a current ratio of 2.28, a quick ratio of 2.15 and a debt-to-equity ratio of 5.68.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.01). The business had revenue of $8.06 million during the quarter, compared to analysts’ expectations of $9.05 million. Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 493.14%. During the same quarter in the previous year, the company posted ($0.61) EPS. Research analysts expect that Marinus Pharmaceuticals will post -1.88 EPS for the current year.

Institutional Trading of Marinus Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Point72 DIFC Ltd acquired a new stake in shares of Marinus Pharmaceuticals during the second quarter worth $28,000. SG Americas Securities LLC acquired a new stake in Marinus Pharmaceuticals in the 2nd quarter worth about $34,000. AQR Capital Management LLC grew its holdings in Marinus Pharmaceuticals by 70.3% in the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 12,934 shares during the period. Jacobs Levy Equity Management Inc. purchased a new stake in Marinus Pharmaceuticals in the 1st quarter valued at about $384,000. Finally, Trexquant Investment LP purchased a new position in shares of Marinus Pharmaceuticals during the 4th quarter worth about $553,000. 98.80% of the stock is owned by hedge funds and other institutional investors.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.